- Home
- YGMZ vs LIXT Comparison
YGMZ vs LIXT Comparison
Compare YGMZ & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- LIXT
- Stock Information
- Founded
- YGMZ 2002
- LIXT 2005
- Country
- YGMZ China
- LIXT United States
- Employees
- YGMZ N/A
- LIXT N/A
- Industry
- YGMZ Transportation Services
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- YGMZ Consumer Discretionary
- LIXT Health Care
- Exchange
- YGMZ Nasdaq
- LIXT Nasdaq
- Market Cap
- YGMZ 7.0M
- LIXT 6.3M
- IPO Year
- YGMZ 2020
- LIXT N/A
- Fundamental
- Price
- YGMZ $0.72
- LIXT $1.27
- Analyst Decision
- YGMZ
- LIXT
- Analyst Count
- YGMZ 0
- LIXT 0
- Target Price
- YGMZ N/A
- LIXT N/A
- AVG Volume (30 Days)
- YGMZ 44.8K
- LIXT 156.1K
- Earning Date
- YGMZ 01-01-0001
- LIXT 03-18-2025
- Dividend Yield
- YGMZ N/A
- LIXT N/A
- EPS Growth
- YGMZ N/A
- LIXT N/A
- EPS
- YGMZ N/A
- LIXT N/A
- Revenue
- YGMZ $55,805,416.00
- LIXT N/A
- Revenue This Year
- YGMZ N/A
- LIXT N/A
- Revenue Next Year
- YGMZ N/A
- LIXT N/A
- P/E Ratio
- YGMZ N/A
- LIXT N/A
- Revenue Growth
- YGMZ N/A
- LIXT N/A
- 52 Week Low
- YGMZ $0.64
- LIXT $1.25
- 52 Week High
- YGMZ $6.24
- LIXT $4.40
- Technical
- Relative Strength Index (RSI)
- YGMZ 44.09
- LIXT 28.82
- Support Level
- YGMZ $0.68
- LIXT $1.35
- Resistance Level
- YGMZ $1.05
- LIXT $3.00
- Average True Range (ATR)
- YGMZ 0.11
- LIXT 0.26
- MACD
- YGMZ -0.00
- LIXT -0.13
- Stochastic Oscillator
- YGMZ 19.66
- LIXT 1.15
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. Its segments are the trucking business, car owner services business, and liquor distribution business. It generates the majority of its revenue from the trucking segment.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.